EDT Aligos Therapeutics (ALGS) files to sell 6.25M shares of common stock for holdersLight Up your Portfolio with Spark:Easily identify ...

Aligos Therapeutics Inc. has disclosed programmed cell death 1 (PDCD1; PD-1; CD279) and/or PD-1 ligand 1 (PD-L1; CD274) and/or PD-1/PD-L1 interaction inhibitors reported to be useful for the treatment ...

Aligos Therapeutics (ALGS) announced positive data from three oral presentations at the 34th Annual Meeting of the Asian Pacific Association ...

Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross... ByInvesting.com ...

SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics ...

Aligos Therapeutics, Inc. (NASDAQ:ALGS – Free Report) – Equities research analysts at HC Wainwright reduced their Q1 2025 earnings per share estimates for shares of Aligos Therapeutics in a ...

SOUTH SAN FRANCISCO, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage ...

Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $3.41 per share versus the Zacks Consensus Estimate of a loss of $1.91. This compares to loss of $5.50 per share a year ago.